Comprehensive review demonstrates AI applications in nanomedicine and precision oncology, highlighting accelerated drug design and resistance mitigation.
This review comprehensively examines the application of artificial intelligence (AI) to revolutionize precision oncology across all phases of drug development, including target discovery and molecular design, nanomedicine delivery, and resistance mitigation. Deep learning, systems biology, and multi-omics analytics enabled by AI accelerate target discovery, lead optimization, and personalized therapy. This study focuses on a new area of AI-driven nanocarrier design, adaptive therapy design, and digital twin clinical decision support. AI bridges the knowledge gap between molecular information and real-world data to enable forecasting, transparent, patient-centered cancer treatment, and the foundation for a data platform to counsel future generations of cancer patients, therapies, and resistance control.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: